An exploration of the factors influencing successful implementation, delivery and outcomes in an intensive care sedation study: process evaluation of the A2B RCT

Choice of sedation of critically ill patients is a core element of intensive care practice. The alpha 2 agonists for sedation to produce better outcomes from critical illness (A2B) trial tested the effectiveness of two alpha agonist sedatives versus propofol in reducing time on mechanical ventilatio...

Full description

Saved in:
Bibliographic Details
Published in:Health technology assessment (Winchester, England) pp. 1 - 18
Main Authors: Aitken, Leanne M, Emerson, Lydia M, Kydonaki, Kalliopi, Blackwood, Bronagh, Creagh-Brown, Ben, Lone, Nazir, McKenzie, Cathrine, Parker, Richard, Reade, Michael C, Weir, Christopher J, Wise, Matt P, Walsh, Timothy S
Format: Journal Article
Language:English
Published: England NIHR Journals Library 12.11.2025
Subjects:
ISSN:2046-4924, 2046-4924
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract Choice of sedation of critically ill patients is a core element of intensive care practice. The alpha 2 agonists for sedation to produce better outcomes from critical illness (A2B) trial tested the effectiveness of two alpha agonist sedatives versus propofol in reducing time on mechanical ventilation in 38 intensive care units in the United Kingdom. To evaluate both how this complex trial was implemented and how this may have influenced trial outcomes, an understanding of the contextual and practice variation across multiple sites was required. The aim of this process evaluation of the A2B trial was to determine how the intervention was delivered, the extent to which it was delivered as intended and the impact this had on outcomes. Specifically, we aimed to: Establish the degree to which the A2B intervention was delivered as intended, specifically in relation to fidelity, dose and reach across patients. Understand factors that impacted on successful delivery of both the A2B intervention and trial, in relation to attitudes and perceptions of staff, including context and standard care. A mixed-methods, multiphase design was used following extensive pre-trial exploration of current practice. Quantitative data were drawn from the main trial database covering 38 sites to assess the intervention's fidelity, dose and reach in each site. Data were analysed descriptively and provided a low-moderate-high rating. Qualitative data were collected by interviews mid trial (phase 1) and end of trial (phase 2). Participants were recruited from a random sample of 30 intensive care units active at the time of sampling and included the principal investigator, research nurses and clinical staff. Semistructured interviews, informed by the trial's logic model, lasted 45-60 minutes. Data collection focused on whether the intervention could be delivered as intended, factors that impacted upon successful delivery and understanding intervention adherence. Analysis used a framework approach based on the logic model. Data collection and qualitative analyses were completed prior to knowing the primary results of the trial. Site intervention adherence ratings for fidelity, dose and reach were low (4), moderate (20) and high (14). Participants from 12 intensive care units in each of phase 1 (33 staff) and phase 2 (36 staff) provided qualitative data; participating intensive care units differed between phases. Factors identified in phase 1 focused on intervention delivery and trial conduct and incorporated both organisational and participant-related factors. In phase 2, participant-related factors included clinician preference, individual equipoise, clinician resistance and staff capability and capacity, while A2B trial-related factors included concerns relating to safety and side effects, overnight deep sedation practice, patient comfort and trial documentation. Many of these factors were impacted by the COVID-19 pandemic, particularly in regard to staffing numbers and experience. Due to the impact of the COVID-19 pandemic, most data collection occurred remotely through video-conferencing rather than planned at site observation and interviews. Optimal sedation practice is influenced by multiple factors related to clinician perceptions, capacity and capability. Priorities in care focus on short-term safety and comfort. Limitations in staffing mean that longer-term consequences related to recovery and rehabilitation are second tier considerations. Findings highlight the multiple contextual factors, including both organisational and participant-related characteristics, that should be considered when planning both clinical trials and changes to routine care. Multiple strategies for achieving behaviour change when implementing complex interventions are essential. This article presents independent research funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme as award number 16/93/01.
AbstractList Choice of sedation of critically ill patients is a core element of intensive care practice. The alpha 2 agonists for sedation to produce better outcomes from critical illness (A2B) trial tested the effectiveness of two alpha agonist sedatives versus propofol in reducing time on mechanical ventilation in 38 intensive care units in the United Kingdom. To evaluate both how this complex trial was implemented and how this may have influenced trial outcomes, an understanding of the contextual and practice variation across multiple sites was required. The aim of this process evaluation of the A2B trial was to determine how the intervention was delivered, the extent to which it was delivered as intended and the impact this had on outcomes. Specifically, we aimed to: Establish the degree to which the A2B intervention was delivered as intended, specifically in relation to fidelity, dose and reach across patients. Understand factors that impacted on successful delivery of both the A2B intervention and trial, in relation to attitudes and perceptions of staff, including context and standard care. A mixed-methods, multiphase design was used following extensive pre-trial exploration of current practice. Quantitative data were drawn from the main trial database covering 38 sites to assess the intervention's fidelity, dose and reach in each site. Data were analysed descriptively and provided a low-moderate-high rating. Qualitative data were collected by interviews mid trial (phase 1) and end of trial (phase 2). Participants were recruited from a random sample of 30 intensive care units active at the time of sampling and included the principal investigator, research nurses and clinical staff. Semistructured interviews, informed by the trial's logic model, lasted 45-60 minutes. Data collection focused on whether the intervention could be delivered as intended, factors that impacted upon successful delivery and understanding intervention adherence. Analysis used a framework approach based on the logic model. Data collection and qualitative analyses were completed prior to knowing the primary results of the trial. Site intervention adherence ratings for fidelity, dose and reach were low (4), moderate (20) and high (14). Participants from 12 intensive care units in each of phase 1 (33 staff) and phase 2 (36 staff) provided qualitative data; participating intensive care units differed between phases. Factors identified in phase 1 focused on intervention delivery and trial conduct and incorporated both organisational and participant-related factors. In phase 2, participant-related factors included clinician preference, individual equipoise, clinician resistance and staff capability and capacity, while A2B trial-related factors included concerns relating to safety and side effects, overnight deep sedation practice, patient comfort and trial documentation. Many of these factors were impacted by the COVID-19 pandemic, particularly in regard to staffing numbers and experience. Due to the impact of the COVID-19 pandemic, most data collection occurred remotely through video-conferencing rather than planned at site observation and interviews. Optimal sedation practice is influenced by multiple factors related to clinician perceptions, capacity and capability. Priorities in care focus on short-term safety and comfort. Limitations in staffing mean that longer-term consequences related to recovery and rehabilitation are second tier considerations. Findings highlight the multiple contextual factors, including both organisational and participant-related characteristics, that should be considered when planning both clinical trials and changes to routine care. Multiple strategies for achieving behaviour change when implementing complex interventions are essential. This article presents independent research funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme as award number 16/93/01.
Background Choice of sedation of critically ill patients is a core element of intensive care practice. The alpha 2 agonists for sedation to produce better outcomes from critical illness (A2B) trial tested the effectiveness of two alpha agonist sedatives versus propofol in reducing time on mechanical ventilation in 38 intensive care units in the United Kingdom. To evaluate both how this complex trial was implemented and how this may have influenced trial outcomes, an understanding of the contextual and practice variation across multiple sites was required. Aim and objectives The aim of this process evaluation of the A2B trial was to determine how the intervention was delivered, the extent to which it was delivered as intended and the impact this had on outcomes. Specifically, we aimed to: Establish the degree to which the A2B intervention was delivered as intended, specifically in relation to fidelity, dose and reach across patients. Understand factors that impacted on successful delivery of both the A2B intervention and trial, in relation to attitudes and perceptions of staff, including context and standard care. Design and methods A mixed-methods, multiphase design was used following extensive pre-trial exploration of current practice. Quantitative data were drawn from the main trial database covering 38 sites to assess the intervention’s fidelity, dose and reach in each site. Data were analysed descriptively and provided a low-moderate-high rating. Qualitative data were collected by interviews mid trial (phase 1) and end of trial (phase 2). Participants were recruited from a random sample of 30 intensive care units active at the time of sampling and included the principal investigator, research nurses and clinical staff. Semistructured interviews, informed by the trial’s logic model, lasted 45–60 minutes. Data collection focused on whether the intervention could be delivered as intended, factors that impacted upon successful delivery and understanding intervention adherence. Analysis used a framework approach based on the logic model. Data collection and qualitative analyses were completed prior to knowing the primary results of the trial. Results Site intervention adherence ratings for fidelity, dose and reach were low (4), moderate (20) and high (14). Participants from 12 intensive care units in each of phase 1 (33 staff) and phase 2 (36 staff) provided qualitative data; participating intensive care units differed between phases. Factors identified in phase 1 focused on intervention delivery and trial conduct and incorporated both organisational and participant-related factors. In phase 2, participant-related factors included clinician preference, individual equipoise, clinician resistance and staff capability and capacity, while A2B trial-related factors included concerns relating to safety and side effects, overnight deep sedation practice, patient comfort and trial documentation. Many of these factors were impacted by the COVID-19 pandemic, particularly in regard to staffing numbers and experience. Limitations Due to the impact of the COVID-19 pandemic, most data collection occurred remotely through video-conferencing rather than planned at site observation and interviews. Conclusion Optimal sedation practice is influenced by multiple factors related to clinician perceptions, capacity and capability. Priorities in care focus on short-term safety and comfort. Limitations in staffing mean that longer-term consequences related to recovery and rehabilitation are second tier considerations. Future work Findings highlight the multiple contextual factors, including both organisational and participant-related characteristics, that should be considered when planning both clinical trials and changes to routine care. Multiple strategies for achieving behaviour change when implementing complex interventions are essential. Funding This article presents independent research funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme as award number 16/93/01. Plain language summary Patients in the intensive care unit receive pain-killers and sedatives to keep them comfortable and reduce pain. However, some patients are more deeply sedated than needed, and improving sedation and pain management is difficult. The Alpha 2 agonists for sedation to produce better outcomes from critical illness trial compared the usual sedative prescribed in intensive care unit (propofol) with medications called ‘alpha-2 agonists’ that have both sedative and pain-killing actions. We wanted to see if patients were more awake and comfortable with alpha-2 agonists and whether they came off the breathing machine quicker. Alongside the trial, we conducted a process evaluation to evaluate if study sedatives were given to patients as intended. We also wanted to evaluate if the usual sedative practice, staffing and other considerations affected how nurses and doctors delivered the sedatives. We conducted interviews with nurses and doctors who cared for trial participants, and the research nurses and doctors involved in the trial to find out their opinion. Interviews were conducted midway through (phase 1) and at the end (phase 2) of the trial. Data showed that from 38 intensive care units, 34 complied with delivering the sedation care as it was intended to a high or moderate level. Interview topics from 33 staff in 12 intensive care units (phase 1) provided a picture of how the sedative medicines were delivered to patients and how the A2B trial was implemented. Interview topics from 36 staff in 12 intensive care units (phase 2) described the clinicians’ sedative preferences, their level of comfort with uncertainty, any resistance they had to the trial, and staff skills and knowledge. Other topics involved concerns about patient safety, possible side effects, practices for deep sedation overnight, patient comfort, and management of trial paperwork. We concluded that sedation practice depends on factors related to clinical staff’s opinions, staffing levels and skills. The priorities for care raised by participants are patient safety and comfort.
Choice of sedation of critically ill patients is a core element of intensive care practice. The alpha 2 agonists for sedation to produce better outcomes from critical illness (A2B) trial tested the effectiveness of two alpha agonist sedatives versus propofol in reducing time on mechanical ventilation in 38 intensive care units in the United Kingdom. To evaluate both how this complex trial was implemented and how this may have influenced trial outcomes, an understanding of the contextual and practice variation across multiple sites was required.BackgroundChoice of sedation of critically ill patients is a core element of intensive care practice. The alpha 2 agonists for sedation to produce better outcomes from critical illness (A2B) trial tested the effectiveness of two alpha agonist sedatives versus propofol in reducing time on mechanical ventilation in 38 intensive care units in the United Kingdom. To evaluate both how this complex trial was implemented and how this may have influenced trial outcomes, an understanding of the contextual and practice variation across multiple sites was required.The aim of this process evaluation of the A2B trial was to determine how the intervention was delivered, the extent to which it was delivered as intended and the impact this had on outcomes. Specifically, we aimed to: Establish the degree to which the A2B intervention was delivered as intended, specifically in relation to fidelity, dose and reach across patients. Understand factors that impacted on successful delivery of both the A2B intervention and trial, in relation to attitudes and perceptions of staff, including context and standard care.Aim and objectivesThe aim of this process evaluation of the A2B trial was to determine how the intervention was delivered, the extent to which it was delivered as intended and the impact this had on outcomes. Specifically, we aimed to: Establish the degree to which the A2B intervention was delivered as intended, specifically in relation to fidelity, dose and reach across patients. Understand factors that impacted on successful delivery of both the A2B intervention and trial, in relation to attitudes and perceptions of staff, including context and standard care.A mixed-methods, multiphase design was used following extensive pre-trial exploration of current practice. Quantitative data were drawn from the main trial database covering 38 sites to assess the intervention's fidelity, dose and reach in each site. Data were analysed descriptively and provided a low-moderate-high rating. Qualitative data were collected by interviews mid trial (phase 1) and end of trial (phase 2). Participants were recruited from a random sample of 30 intensive care units active at the time of sampling and included the principal investigator, research nurses and clinical staff. Semistructured interviews, informed by the trial's logic model, lasted 45-60 minutes. Data collection focused on whether the intervention could be delivered as intended, factors that impacted upon successful delivery and understanding intervention adherence. Analysis used a framework approach based on the logic model. Data collection and qualitative analyses were completed prior to knowing the primary results of the trial.Design and methodsA mixed-methods, multiphase design was used following extensive pre-trial exploration of current practice. Quantitative data were drawn from the main trial database covering 38 sites to assess the intervention's fidelity, dose and reach in each site. Data were analysed descriptively and provided a low-moderate-high rating. Qualitative data were collected by interviews mid trial (phase 1) and end of trial (phase 2). Participants were recruited from a random sample of 30 intensive care units active at the time of sampling and included the principal investigator, research nurses and clinical staff. Semistructured interviews, informed by the trial's logic model, lasted 45-60 minutes. Data collection focused on whether the intervention could be delivered as intended, factors that impacted upon successful delivery and understanding intervention adherence. Analysis used a framework approach based on the logic model. Data collection and qualitative analyses were completed prior to knowing the primary results of the trial.Site intervention adherence ratings for fidelity, dose and reach were low (4), moderate (20) and high (14). Participants from 12 intensive care units in each of phase 1 (33 staff) and phase 2 (36 staff) provided qualitative data; participating intensive care units differed between phases. Factors identified in phase 1 focused on intervention delivery and trial conduct and incorporated both organisational and participant-related factors. In phase 2, participant-related factors included clinician preference, individual equipoise, clinician resistance and staff capability and capacity, while A2B trial-related factors included concerns relating to safety and side effects, overnight deep sedation practice, patient comfort and trial documentation. Many of these factors were impacted by the COVID-19 pandemic, particularly in regard to staffing numbers and experience.ResultsSite intervention adherence ratings for fidelity, dose and reach were low (4), moderate (20) and high (14). Participants from 12 intensive care units in each of phase 1 (33 staff) and phase 2 (36 staff) provided qualitative data; participating intensive care units differed between phases. Factors identified in phase 1 focused on intervention delivery and trial conduct and incorporated both organisational and participant-related factors. In phase 2, participant-related factors included clinician preference, individual equipoise, clinician resistance and staff capability and capacity, while A2B trial-related factors included concerns relating to safety and side effects, overnight deep sedation practice, patient comfort and trial documentation. Many of these factors were impacted by the COVID-19 pandemic, particularly in regard to staffing numbers and experience.Due to the impact of the COVID-19 pandemic, most data collection occurred remotely through video-conferencing rather than planned at site observation and interviews.LimitationsDue to the impact of the COVID-19 pandemic, most data collection occurred remotely through video-conferencing rather than planned at site observation and interviews.Optimal sedation practice is influenced by multiple factors related to clinician perceptions, capacity and capability. Priorities in care focus on short-term safety and comfort. Limitations in staffing mean that longer-term consequences related to recovery and rehabilitation are second tier considerations.ConclusionOptimal sedation practice is influenced by multiple factors related to clinician perceptions, capacity and capability. Priorities in care focus on short-term safety and comfort. Limitations in staffing mean that longer-term consequences related to recovery and rehabilitation are second tier considerations.Findings highlight the multiple contextual factors, including both organisational and participant-related characteristics, that should be considered when planning both clinical trials and changes to routine care. Multiple strategies for achieving behaviour change when implementing complex interventions are essential.Future workFindings highlight the multiple contextual factors, including both organisational and participant-related characteristics, that should be considered when planning both clinical trials and changes to routine care. Multiple strategies for achieving behaviour change when implementing complex interventions are essential.This article presents independent research funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme as award number 16/93/01.FundingThis article presents independent research funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme as award number 16/93/01.
Author Emerson, Lydia M
McKenzie, Cathrine
Weir, Christopher J
Lone, Nazir
Kydonaki, Kalliopi
Parker, Richard
Creagh-Brown, Ben
Walsh, Timothy S
Reade, Michael C
Wise, Matt P
Aitken, Leanne M
Blackwood, Bronagh
Author_xml – sequence: 1
  givenname: Leanne M
  orcidid: 0000-0001-5722-9090
  surname: Aitken
  fullname: Aitken, Leanne M
  organization: School of Health & Medical Sciences, City St George’s, University of London, London, UK
– sequence: 2
  givenname: Lydia M
  orcidid: 0000-0002-4250-5758
  surname: Emerson
  fullname: Emerson, Lydia M
  organization: School of Health & Medical Sciences, City St George’s, University of London, London, UK
– sequence: 3
  givenname: Kalliopi
  orcidid: 0000-0003-3400-8230
  surname: Kydonaki
  fullname: Kydonaki, Kalliopi
  organization: Faculty of Nursing, National and Kapodistrian University of Athens, Athens, Greece
– sequence: 4
  givenname: Bronagh
  orcidid: 0000-0002-4583-5381
  surname: Blackwood
  fullname: Blackwood, Bronagh
  organization: School of Medicine, Dentistry and Biomedical Sciences, Queens University Belfast, Belfast, UK
– sequence: 5
  givenname: Ben
  orcidid: 0000-0002-4397-1232
  surname: Creagh-Brown
  fullname: Creagh-Brown, Ben
  organization: Department of Critical Care, Royal Surrey NHS Foundation Trust, Guildford, UK
– sequence: 6
  givenname: Nazir
  orcidid: 0000-0003-2707-2779
  surname: Lone
  fullname: Lone, Nazir
  organization: Department of Anaesthesia, Critical Care and Pain Medicine, Usher Institute, University of Edinburgh, Edinburgh, UK
– sequence: 7
  givenname: Cathrine
  orcidid: 0000-0002-5190-9711
  surname: McKenzie
  fullname: McKenzie, Cathrine
  organization: School of Medicine, NIHR Southampton Biomedical Research Centre, University of Southampton, and Perioperative and Critical Care Theme, Department of Pharmacy and Critical Care, University Hospital Southampton, Southampton, UK
– sequence: 8
  givenname: Richard
  orcidid: 0000-0002-2658-5022
  surname: Parker
  fullname: Parker, Richard
  organization: Edinburgh Clinical Trials Unit, Usher Institute, University of Edinburgh, Edinburgh, UK
– sequence: 9
  givenname: Michael C
  orcidid: 0000-0003-1570-0707
  surname: Reade
  fullname: Reade, Michael C
  organization: Medical School, University of Queensland, Brisbane, Australia
– sequence: 10
  givenname: Christopher J
  orcidid: 0000-0002-6494-4903
  surname: Weir
  fullname: Weir, Christopher J
  organization: Edinburgh Clinical Trials Unit, Usher Institute, University of Edinburgh, Edinburgh, UK
– sequence: 11
  givenname: Matt P
  orcidid: 0000-0002-2763-4316
  surname: Wise
  fullname: Wise, Matt P
  organization: Adult Critical Care, University Hospital of Wales, Cardiff, UK
– sequence: 12
  givenname: Timothy S
  orcidid: 0000-0002-3590-8540
  surname: Walsh
  fullname: Walsh, Timothy S
  organization: Department of Anaesthesia, Critical Care and Pain Medicine, Usher Institute, University of Edinburgh, Edinburgh, UK
BackLink https://www.ncbi.nlm.nih.gov/pubmed/41240055$$D View this record in MEDLINE/PubMed
BookMark eNpVkdtu1DAQhi1URA8g8QTIl1ywMD4kdbjbrmgpqoSEFnEZTexJceXYi51U7OPwps122wI3tmfmn2_G-o_ZQUyRGHst4L1SAj5cfFn_gFrCM3YkQdcL3Uh98M_7kB2XcgOgRV2JF-xQC6kBquqI_VlGTr83IWUcfYo89Xz8SbxHO6ZcuI99mChaH695maylUvopcD9sAg0Ux_umd9xR8LeUtxyj42kabRpo1zzH8zlSLHOZW8zEC7n9pDJObvuRb3LaUTndYpj-22Epz_i31fole95jKPTq4T5h388_rVefF1dfLy5Xy6uFFaaBBSqNjQCjlFVOYgeuwxpl1TXYV6YzomoItFGA0hlVa9FVEsxcbYS0lXPqhF3uuS7hTbvJfsC8bRP69j6R8nWLefQ2UKtqMKIDic7VuoeZh0b3lXVgmhmpZtbbPWv-3a-JytgOvlgKASOlqbRKnkohmlMjZumbB-nUDeSeBj9a9JdlcyolU_8kEdDu3G8f3Vd36TKiQQ
Cites_doi 10.1136/bmj.h1258
10.1177/1751143716663749
10.1164/rccm.202206-1208OC
10.1001/jama.2025.7200
10.1007/s00134-021-06356-8
10.1186/cc8956
10.1177/1559827617745479
10.1093/ajhp/zxab202
10.1136/bmjopen-2023-078645
10.1136/bmjopen-2023-081637
10.1056/NEJMoa1906759
10.1108/01443570410552108
10.2147/JHL.S221141
10.1186/s13012-017-0605-9
10.12968/ajmw.2010.4.2.47612
10.1186/s12913-016-1292-y
10.1016/j.anclin.2017.01.009
10.1056/NEJMoa1904710
10.1097/CCM.0000000000000882
ContentType Journal Article
DBID AAYXX
CITATION
NPM
7X8
DOA
DOI 10.3310/GJTW0620
DatabaseName CrossRef
PubMed
MEDLINE - Academic
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
PubMed
MEDLINE - Academic
DatabaseTitleList PubMed

MEDLINE - Academic
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2046-4924
EndPage 18
ExternalDocumentID oai_doaj_org_article_36081b02add64f0d83a84f5cd0898b93
41240055
10_3310_GJTW0620
Genre Journal Article
GroupedDBID ---
53G
5GY
AAYXX
ADBBV
ADDVE
AENEX
ALMA_UNASSIGNED_HOLDINGS
BAWUL
BCNDV
CITATION
CZQ
DIK
EBS
EJD
F5P
GROUPED_DOAJ
OK1
P2P
P6G
TR2
W2D
NPM
7X8
ID FETCH-LOGICAL-c1890-a34a910833c3d2ab0dba6a25b9af58b8159e04830a2d83641b5208b9a912c5dd3
IEDL.DBID DOA
ISSN 2046-4924
IngestDate Mon Nov 24 19:21:11 EST 2025
Sat Nov 15 17:02:10 EST 2025
Sun Nov 16 02:01:13 EST 2025
Thu Nov 20 00:42:14 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Keywords TRIAL IMPLEMENTATION
PROCESS EVALUATION
RANDOMISED CONTROLLED TRIAL
SEDATION
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c1890-a34a910833c3d2ab0dba6a25b9af58b8159e04830a2d83641b5208b9a912c5dd3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0002-5190-9711
0000-0002-3590-8540
0000-0001-5722-9090
0000-0002-4397-1232
0000-0003-1570-0707
0000-0002-4250-5758
0000-0002-4583-5381
0000-0002-6494-4903
0000-0003-2707-2779
0000-0002-2763-4316
0000-0003-3400-8230
0000-0002-2658-5022
OpenAccessLink https://doaj.org/article/36081b02add64f0d83a84f5cd0898b93
PMID 41240055
PQID 3272119781
PQPubID 23479
PageCount 18
ParticipantIDs doaj_primary_oai_doaj_org_article_36081b02add64f0d83a84f5cd0898b93
proquest_miscellaneous_3272119781
pubmed_primary_41240055
crossref_primary_10_3310_GJTW0620
PublicationCentury 2000
PublicationDate 2025-Nov-12
PublicationDateYYYYMMDD 2025-11-12
PublicationDate_xml – month: 11
  year: 2025
  text: 2025-Nov-12
  day: 12
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
PublicationTitle Health technology assessment (Winchester, England)
PublicationTitleAlternate Health Technol Assess
PublicationYear 2025
Publisher NIHR Journals Library
Publisher_xml – name: NIHR Journals Library
References Olsen (key2025111520425100_ref3-bib3) 2020; 382
Walsh (key2025111520425100_ref4-bib4) 2023; 13
Beer (key2025111520425100_ref14-bib14) 2000; 78
Walsh (key2025111520425100_ref10-bib10) 2025; 334
Atkins (key2025111520425100_ref22-bib22) 2017; 12
Burnes (key2025111520425100_ref15-bib15) 2004; 24
Aitken (key2025111520425100_ref9-bib9) 2024; 14
Shehabi (key2025111520425100_ref7-bib7) 2019; 380
Furber (key2025111520425100_ref11-bib11) 2010; 4
McNett (key2025111520425100_ref13-bib13) 2020; 2
Jackson (key2025111520425100_ref1-bib1) 2010; 14
Shehabi (key2025111520425100_ref12-bib12) 2021; 47
Pattison (key2025111520425100_ref16-bib16) 2017; 18
Eadie (key2025111520425100_ref5-bib5) 2022; 23
Shehabi (key2025111520425100_ref18-bib18) 2023; 207
European Medicines Agency (key2025111520425100_ref17-bib17) 2022
Parker (key2025111520425100_ref2-bib2) 2015; 43
Nguyen (key2025111520425100_ref6-bib6) 2017; 35
Kristensen (key2025111520425100_ref19-bib19) 2016; 16
Moore (key2025111520425100_ref8-bib8) 2015; 350
Gottlieb (key2025111520425100_ref20-bib20) 2021; 13
Arlinghaus (key2025111520425100_ref21-bib21) 2018; 12
Balakrishna (key2025111520425100_ref23-bib23) 2021; 78
References_xml – volume: 350
  start-page: h1258
  year: 2015
  ident: key2025111520425100_ref8-bib8
  article-title: Process evaluation of complex interventions: Medical Research Council guidance
  publication-title: BMJ
  doi: 10.1136/bmj.h1258
– volume: 18
  start-page: 36
  year: 2017
  ident: key2025111520425100_ref16-bib16
  article-title: Exploring obstacles to critical care trials in the UK: a qualitative investigation
  publication-title: J Intensive Care Soc
  doi: 10.1177/1751143716663749
– volume: 207
  start-page: 876
  year: 2023
  ident: key2025111520425100_ref18-bib18
  article-title: Dexmedetomidine and propofol sedation in critically ill patients and dose-associated 90-day mortality: a secondary cohort analysis of a randomized controlled trial (SPICE III)
  publication-title: Am J Respir Crit Care Med
  doi: 10.1164/rccm.202206-1208OC
– volume: 334
  start-page: 32
  year: 2025
  ident: key2025111520425100_ref10-bib10
  article-title: Dexmedetomidine- or clonidine-based sedation compared with propofol in critically ill patients: the A2B randomized clinical trial
  publication-title: JAMA
  doi: 10.1001/jama.2025.7200
– volume: 47
  start-page: 455
  year: 2021
  ident: key2025111520425100_ref12-bib12
  article-title: Early sedation with dexmedetomidine in ventilated critically ill patients and heterogeneity of treatment effect in the SPICE III randomised controlled trial
  publication-title: Intensive Care Med
  doi: 10.1007/s00134-021-06356-8
– volume: 14
  start-page: R59
  year: 2010
  ident: key2025111520425100_ref1-bib1
  article-title: A systematic review of the impact of sedation practice in the ICU on resource use, costs and patient safety
  publication-title: Crit Care
  doi: 10.1186/cc8956
– volume: 78
  start-page: 133
  year: 2000
  ident: key2025111520425100_ref14-bib14
  article-title: Cracking the code of change
  publication-title: Harv Bus Rev
– volume: 12
  start-page: 113
  year: 2018
  ident: key2025111520425100_ref21-bib21
  article-title: Advocating for behavior change with education
  publication-title: Am J Lifestyle Med
  doi: 10.1177/1559827617745479
– volume: 23
  start-page: 1
  year: 2022
  ident: key2025111520425100_ref5-bib5
  article-title: Clinical pharmacist’s views on the role of alpha-2-agonists in practice and research for the management of agitation, sedation, and delirium (ASD)
  publication-title: J Intensive Care Soc
– volume: 78
  start-page: 1952
  year: 2021
  ident: key2025111520425100_ref23-bib23
  article-title: An examination of sedation requirements and practices for mechanically ventilated critically ill patients with COVID-19
  publication-title: Am J Health Syst Pharm
  doi: 10.1093/ajhp/zxab202
– volume: 13
  start-page: e078645
  year: 2023
  ident: key2025111520425100_ref4-bib4
  article-title: Alpha 2 agonists for sedation to produce better outcomes from critical illness (A2B Trial): protocol for a multicentre phase 3 pragmatic clinical and cost-effectiveness randomised trial in the UK
  publication-title: BMJ Open
  doi: 10.1136/bmjopen-2023-078645
– volume: 14
  start-page: e081637
  year: 2024
  ident: key2025111520425100_ref9-bib9
  article-title: Alpha 2 agonists for sedation to produce better outcomes from critical illness (A2B trial): protocol for a mixed-methods process evaluation of a randomised controlled trial
  publication-title: BMJ Open
  doi: 10.1136/bmjopen-2023-081637
– volume-title: Dexdor – Direct healthcare professional Communication (DHPC)
  year: 2022
  ident: key2025111520425100_ref17-bib17
– volume: 382
  start-page: 1103
  year: 2020
  ident: key2025111520425100_ref3-bib3
  article-title: Nonsedation or light sedation in critically ill, mechanically ventilated patients
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1906759
– volume: 24
  start-page: 886
  year: 2004
  ident: key2025111520425100_ref15-bib15
  article-title: Emergent change and planned change – competitors or allies?
  publication-title: Int J Oper Prod Man
  doi: 10.1108/01443570410552108
– volume: 2
  start-page: e0301
  year: 2020
  ident: key2025111520425100_ref13-bib13
  article-title: A scoping review of implementation science in adult critical care settings
  publication-title: Crit Care Explor
– volume: 13
  start-page: 169
  year: 2021
  ident: key2025111520425100_ref20-bib20
  article-title: Creating empowering conditions for nurses with workplace autonomy and agency: how healthcare leaders could be guided by strengths-based nursing and healthcare leadership (SBNH-L)
  publication-title: J Healthc Leadersh
  doi: 10.2147/JHL.S221141
– volume: 12
  start-page: 77
  year: 2017
  ident: key2025111520425100_ref22-bib22
  article-title: A guide to using the Theoretical Domains Framework of behaviour change to investigate implementation problems
  publication-title: Implement Sci
  doi: 10.1186/s13012-017-0605-9
– volume: 4
  start-page: 97
  year: 2010
  ident: key2025111520425100_ref11-bib11
  article-title: Framework analysis: a method for analysing qualitative data
  publication-title: Afr J Midwifery Women’s Health
  doi: 10.12968/ajmw.2010.4.2.47612
– volume: 16
  start-page: 48
  year: 2016
  ident: key2025111520425100_ref19-bib19
  article-title: Implementing research results in clinical practice – the experiences of healthcare professionals
  publication-title: BMC Health Serv Res
  doi: 10.1186/s12913-016-1292-y
– volume: 35
  start-page: 233
  year: 2017
  ident: key2025111520425100_ref6-bib6
  article-title: Alpha-2 agonists
  publication-title: Anesthesiol Clin
  doi: 10.1016/j.anclin.2017.01.009
– volume: 380
  start-page: 2506
  year: 2019
  ident: key2025111520425100_ref7-bib7
  article-title: Early sedation with dexmedetomidine in critically ill patients
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1904710
– volume: 43
  start-page: 1121
  year: 2015
  ident: key2025111520425100_ref2-bib2
  article-title: Posttraumatic stress disorder in critical illness survivors: a metaanalysis
  publication-title: Crit Care Med
  doi: 10.1097/CCM.0000000000000882
SSID ssj0041651
Score 2.459997
SecondaryResourceType online_first
Snippet Choice of sedation of critically ill patients is a core element of intensive care practice. The alpha 2 agonists for sedation to produce better outcomes from...
Background Choice of sedation of critically ill patients is a core element of intensive care practice. The alpha 2 agonists for sedation to produce better...
SourceID doaj
proquest
pubmed
crossref
SourceType Open Website
Aggregation Database
Index Database
StartPage 1
SubjectTerms process evaluation
randomised controlled trial
sedation
trial implementation
Title An exploration of the factors influencing successful implementation, delivery and outcomes in an intensive care sedation study: process evaluation of the A2B RCT
URI https://www.ncbi.nlm.nih.gov/pubmed/41240055
https://www.proquest.com/docview/3272119781
https://doaj.org/article/36081b02add64f0d83a84f5cd0898b93
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAON
  databaseName: DOAJ Directory of Open Access Journals
  customDbUrl:
  eissn: 2046-4924
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0041651
  issn: 2046-4924
  databaseCode: DOA
  dateStart: 20010101
  isFulltext: true
  titleUrlDefault: https://www.doaj.org/
  providerName: Directory of Open Access Journals
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Na9wwEBVtKKWX0O9sm4Yp9BgTWfKHlNsm5IOShBK2dG9GsiRYSLwhuw705_SfZkayk1xKLz3aRkjMG3me8Pg9xr4ZwSslQ8hkq8nCTMvMIOxZrZw03jqfuyjielZfXKj5XP94YvVFPWFJHjgFbk9WWLQsF7gPqyJwp6RRRShbx5VWVkedT17r8TCV3sHIMso8Sc1K5C97J99nv3hFnt5Pik_U6P87sYwF5vg12xyYIUzTit6wZ757y16eD9--37E_0w587JiLwYRlACRvMBjmwGJwG8FSBKs-2iCG_goW12ODOA3aBeevqBPjN5jOwbJfY8J5GozXsBjb2YH6wWDlk98SRAnafbhJ_xTAo0D4uIapOIDLw9l79vP4aHZ4mg0GC1mbK80zIwuDdEFJ2UonjOXOmsqI0moTSmUVUh1PkvPcCIx7VeS2FByDjoNEWzonP7CNbtn5LQa1RcCD9Vq1ButioZAn1kGW1uRtbq2fsK9j5JubpKPR4PmD0GlGdCbsgCB5eE7K1_EG5kMz5EPzr3zAiUZAG9wp9PnDdH7Zrxop6LRLGl8T9jEh_TAVeXCTHNmn_7GEz-yVIJdgahYU22xjfdv7L-xFe7derG532PN6rnZiut4DBkDxEA
linkProvider Directory of Open Access Journals
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=An+exploration+of+the+factors+influencing+successful+implementation%2C+delivery+and+outcomes+in+an+intensive+care+sedation+study%3A+process+evaluation+of+the+A2B+RCT&rft.jtitle=Health+technology+assessment+%28Winchester%2C+England%29&rft.au=Aitken%2C+Leanne+M&rft.au=Emerson%2C+Lydia+M&rft.au=Kydonaki%2C+Kalliopi&rft.au=Blackwood%2C+Bronagh&rft.date=2025-11-12&rft.eissn=2046-4924&rft.spage=1&rft_id=info:doi/10.3310%2FGJTW0620&rft_id=info%3Apmid%2F41240055&rft.externalDocID=41240055
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2046-4924&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2046-4924&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2046-4924&client=summon